Association of Triglyceride Glucose Index and HOMA IR as Predictors of Vascular Complications of DM Type 2

NCT05695651 | Unknown

• 1 other identifier: sallym
• Study Type: observational
• Target: 56
• Locations: 0 countries
• Sites: N/A

Brief Summary

• Explore the association between Triglyceride glucose index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes.
• Which shows better performance for assessing insulin resistance Triglyceride glucose index or HOMA-IR in clinical practice regardless of diabetes status

Conditions

Type 2 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Investigate the association between TyG index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes

  Investigate the association between TyG index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes

  baseline

Secondary Outcomes (1)

• Percentage of diabetic patients who developed vascular complications.

  baseline

Interventions

triglyceride glucose index and HOMA IR DIAGNOSTIC_TEST

TyG index was calculated as formula: ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2\]. an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance).

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients were diagnosed with diabetes type 2 According to American Diabetes Association

You may qualify if:

• Patients were diagnosed with diabetes type 2 According to American Diabetes Association

You may not qualify if:

• years or young
• Type 1 diabetes or other special types of diabetes
• Suffering from acute complications of diabetes, severe chronic complications, or malignant tumors
• Patients with a diagnosis of urinary tract infection, renal calculi, or primary renal disease.
• Evidence of chronic kidney disease.
• Evidence of Diabetic Kidney Disease and/or Diabetic Nephropathy

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Central Study Contacts

Sally Mamdoh Nathan Wasilly, master

CONTACT

01221553703; mamdouhsally5@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: sahel sleem - assiut

Study Record Dates

• First Submitted: January 10, 2023
• First Posted: January 25, 2023
• Study Start: February 7, 2023
• Primary Completion: January 7, 2025
• Study Completion: March 7, 2025
• Last Updated: January 25, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will share